Pulse Biosciences Begins First Study Using Nanosecond PFA Tech To Treat Benign Thyroid Nodules

Benzinga · 09/02/2025 11:05

Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the first successful procedures in a multicenter IRB-approved study using Pulse Biosciences' nsPFA™ Percutaneous Electrode System for the treatment of benign thyroid nodules (BTNs).